Abstract
In a phase II clinical trial of 5-fluorouracil (5FU) plusN-(phosphonacetyl)-l-aspartate (PALA) therapy administration, a number of slowly developing clinical responses were observed. Because of this, a variety of immune parameters were sequentially studied in 21 patients on this trial. Of the 21 patients studied, 20 provided sufficient samples to compare baseline with subsequent values, 10 of the 20 patients responded to treatment. Responders and non-responders did not differ in any studied parameter at baseline. After 2 months of therapy, non-specific monocyte cytotoxicity (NSMC), antibody-dependent monocyte cytotoxicity (ADMC) and natural killer (NK) activity were higher in the entire study population, but these increases were not statistically significant. When responders and non-responders were evaluated separately, it was apparent that the trend was due solely to the changes observed in the responding patient population. When mean lysis values for each patient group were determined for each studied time point, it was possible to generate a mean area under the cytotoxicity/time curve (AUC) for each studied parameter. NSMC and ADMC did not differ in responders and non-responders. However, NK activity was significantly greater by mean AUC analysis (P = 0.006) in the responding group; NK activity was maintained in the responders, but decreased in non-responders. When lymphocyte and monocyte expression of the surface markers β2-microglobulin, HLA-DR, CD56, HNK-1, CD 16 and interleukin-2 receptor were evaluated, there were no differences among responders and non-responders at baseline by mean AUC analysis or when comparing baseline with non-base-line values. It is concluded that although baseline immunological characteristics do not identify patients who are likely to respond to weekly 5FU and PALA, treatment is not associated with deleterious effects on the immune effector function parameters evaluated in this study, there being no effects on expression of a variety of associated cell-surface molecules.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ades E, Hinson A, Butler L (1986) Natural cytolytic activity in mice with natural or induced cellular defects. Cell Immunol 101: 15
Ardalan B, Singh G, Silberman H (1988) A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or withoutN-(phosphonacetyl)-l-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6: 1053
Ben-Efraim S, Shoval S, Ophin R (1986) The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma. Cancer 22: 43
Berenbaum MC (1979) The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil. Chemotherapy 25: 54
Blomgren SE, Wolberg WH, Kisken WA (1965) Effect of fluoropyrimidines on delayed cutaneous hypersensitivity. Cancer Res 25: 977
Boyum A (1968) Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 21 [Suppl 97]: 7
Freundlich B, Audolovic N (1983) Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J Immunol Methods 62: 31
Goto M, Akio M, Masatoshi S, Kitano M (1981) Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. J Exp Med 154: 204
Grem JS, Allegra CJ (1989) Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. JNCI 81: 1413
Hamilton JM, Sznol M, Friedman MA (1990) 5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer. In: Important advances in oncology. In: DeVita VT, Hellman S, Rosenberg SA (eds) Lippincott, Philadelphia, p 115
Harris J, Sengar D, Stewart T, Hyslop D (1976) The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 37: 1058
Kataoka T, Nakamura M, Iwaguchi T (1985) In vitro inhibition of concanavalin a-induced suppressor t-cells by 5-fluorouracil. Gann 76: 995
Merluzzi V, Last-Barney K, Susskind B, Faanes R (1982) Recovery of humoral and cellular immunity by soluble mediators after 5-fluorouracil-induced immunosuppression. Clin Exp Immunol 50: 318
Mitchell M, DeConti R (1970) Immunosuppression by 5-fluorouracil. Cancer 26: 884
Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JG (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352
Nordman E, Saarimaa H, Toivaneu A (1978) The influence of 5-fluorouracil on cellular and humoral immunity in cancer patients. Cancer 41: 64
O'Dwyer PJ, Paul AR, Walzcak J, Weiner L, Litwin S, Comis R (1990) Phase II study of biochemical modulation of 5-fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8: 1479
Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuka H, Yagi Y (1980) Comparative studies on the immunosuppressive effect among 5′-deoxy-S-fluorouridine, Ftorafur, and 5-fluorouracil. Gann 71: 190
Pross HF, Baines MT, Rubin P, Shragge P, Patterson MS (1981) Spontaneous human lymphocyte mediated cytotoxicity against tumor target cell: IX. The quantitation of natural killer cell activity. J Clin Immunol 1: 51
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889
Sears HF, Atkinson B, Herlyn D, Ernst C, Matties J, Steplewski Z, Hayry P, Koprowski H (1982) The use of monoclonal antibody in a phase I clinical trial of human gastrointestinal tumors. Lancet 1: 762
Sears HF, Herlyn D, Steplewski Z, Koprowski H (1985) Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45: 5910
Shih W, Baumhefner R, Tourtellotte W, Haskett C, Korn E, Fahey J (1983) Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. Clin Exp Immunol 53: 122
Sindelar WF, Maher MM, Herlyn D, Sears HF, Steplewski Z, Koprowski H (1986) Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma 5 [Suppl 1]: S125
Tokuda N, Gondo H, Mayumi H, Kazuto T, Himeno K, Nomoko K (1986) Drug-induced in vitro tolerance to allogeneic antigens. Transplantation 42: 281
Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik P (1989) Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769
Weiner LM, Padavic-Shaller K, Kitson J, Watts P, Krigel RL, Litwin S (1991) Phase I evaluation of combination therapy with interleukin-2 and gamma-interferon. Cancer Res 51: 3910
Wiltrout RH, Taramelli D, Holden HT (1981) Indium-111 assay of macrophage-mediated cytolysis. In: Herscowitz H, Holden HT, Bellanti JA, Gaffar A (eds) Manual of macrophage methodology. Dekker, New York
Wiltrout RH, Taramelli D, Holden HT (1981) Measurement of macrophage mediated cytotoxicity against adherent and non-adherent target cells by release of111Indium-oxide. J Immunol Methods 43: 319
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weiner, L.M., Hudes, G.R., Kitson, J. et al. Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen. Cancer Immunol Immunother 36, 185–190 (1993). https://doi.org/10.1007/BF01741090
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01741090